Vivlion, headquarted in Frankfurt, Germany, provides innovative gene-editing reagents and screening services for the global R&D market. The company's success is based on its proprietary 3Cs technology, which was developed at Goethe University’s Institute of Biochemistry II (IBC2). Vivlion was spun out of Goethe University Frankfurt in 2018.

Vivlion’s proprietary PRCISR^TM CRISPR technology enables next-generation CRISPR screening. For the preparation of gRNA libraries, the technology avoids PCR-amplification of oligo pools as well as restriction and ligation-based cloning, thereby overcoming the major challenges in the generation of conventional libraries. In addition, it decouples sequence diversity and sequence distribution, resulting in uniformly distributed libraries.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The company utilises its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company’s pipeline includes lunresertib, a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib, a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-3467, a pre-clinical Polθ inhibitor programme; RP-1664, a pre-clinical PLK4 inhibitor; as well as several additional, undisclosed pre-clinical programmes.This webinar will comprise two presentations:

1) Martin Wegner, Head of R&D at Vivlion:

Presentation: PRCSR CRISPR: Vivlion's CRISPR-enabled discovery platform

• Vivlion’s proprietary Covalently-Closed-Circular-synthesized (3Cs) technology
• Uniform CRISPR libraries enable more efficient screening
• Targeting the combinatorial search space

2) Jordan Young, Senior Director, Oncology Discovery at Repare Therapeutics:

Presentation: CRISPR-based genetic screens enable the discovery of oncology drug targets, predictive biomarkers, and mechanisms of resistance

• The use of CRISPR genetic screens for oncology target discovery
• Discovery of PKMYT1-CCNE1 synthetic lethality and development of lunreserib
• CRISPR chemical genetic screens for the expansion of the lunresertib patient population and discovery of resistance mechanisms

Webinar Programme (CET time zone):

• 15.00 Welcome and introduction by Karen O'Hanlon Cohrt PhD., Editor-in-chief, CRISPR Medicine News
• 15.05 Martin Wegner, Head of R&D at Vivlion (Frankfurt, Germany) and Jordan Young, Senior Director, Oncology Discovery at Repare Therapeutics (Montreal, Canada)
• 16.00 Q & A with Martin Wegner and Jordan Young
• 16.15 Close by CRISPR Medicine News

Speaker | Title:

Martin Wegner, Head of R&D at Vivlion and Jordan Young, Senior Director, Oncology Discovery at Repare Therapeutics | PRCSR CRISPR: Vivlion's CRISPR-enabled discovery platform | CRISPR-based genetic screens enable the discovery of oncology drug targets, predictive biomarkers, and mechanisms of resistance